Literature DB >> 6155991

Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole.

A J Varghese, G F Whitmore.   

Abstract

Reduction of the nitro group occurred when [14C]misonidazole was treated with zinc dust in aqueous solution in the presence of ammonium chloride. When the reduction mixture was allowed to react with calf thymus DNA or bovine albumin, radioactivity was bound to both DNA and protein. Under the same conditions, misonidazole did not bind to these macromolecules. Analysis of the reduction mixture indicated that the hydroxylamine, amine, and hydrazo derivatives of mizonidazole were the major products. In a number of tissues of C3H mice after administration of [14C]misonidazole, radioactivity was detected in the DNA, RNA, and protein fractions. Similar results were also obtained with Chinese hamster ovary cells incubated with the drug in the absence of oxygen. It is postulated that nitroreduction and binding of the nitroreduction products to macromolecules is a probable mechanism for the mutagenic and cytotoxic properties of misonidazole.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155991

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Imaging hypoxia to improve radiotherapy outcome.

Authors:  Michael R Horsman; Lise Saksø Mortensen; Jørgen B Petersen; Morten Busk; Jens Overgaard
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

2.  Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma.

Authors:  S H Yeh; R S Liu; L C Wu; D J Yang; S H Yen; C W Chang; T W Yu; K L Chou; K Y Chen
Journal:  Eur J Nucl Med       Date:  1996-10

3.  Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging.

Authors:  Zhihao Zha; Lin Zhu; Yajing Liu; Fenghua Du; Hongmei Gan; Jinping Qiao; Hank F Kung
Journal:  Nucl Med Biol       Date:  2011-02-04       Impact factor: 2.408

Review 4.  Optimizing hypoxia detection and treatment strategies.

Authors:  Cameron J Koch; Sydney M Evans
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

5.  Evaluation of hypoxic tissue dynamics with 18F-FMISO PET in a rat model of permanent cerebral ischemia.

Authors:  Santiago Rojas; José Raul Herance; Sergio Abad; Xavier Jiménez; Deborah Pareto; Alba Ruiz; Èlia Torrent; Francisca P Figueiras; Foteini Popota; Francisco J Fernández-Soriano; Anna M Planas; Juan D Gispert
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

6.  Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.

Authors:  G Akel; P Benard; P Canal; G Soula
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?

Authors:  Makiko Suehiro; Paul Burgman; Sean Carlin; Sean Burke; Guangbin Yang; Ouathek Ouerfelli; Christoph Oehler-Janne; Joseph O'Donoghue; Clifton Ling; John Humm
Journal:  Nucl Med Biol       Date:  2009-05-07       Impact factor: 2.408

8.  Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.

Authors:  J M Cline; D E Thrall; R L Page; A J Franko; J A Raleigh
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

9.  A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.

Authors:  C P Lee; G S Payne; A Oregioni; R Ruddle; S Tan; F I Raynaud; D Eaton; M J Campbell; K Cross; G Halbert; M Tracy; J McNamara; B Seddon; M O Leach; P Workman; I Judson
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

10.  Microscopic distribution of misonidazole in mouse tissues.

Authors:  L M Cobb; J Nolan; P O'Neill
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.